Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Lipoprotein-apheresis DFPP has been performed in patients with Lp(a) levels greater than 125 nmol/L. In this report, data will be presented on five hemodialysis patients with significantly elevated Lp(a) levels (>200 nmol/L) who had a history of cardiovascular disease and notable thromboembolic events.
The biological and clinical outcomes related to Lipoprotein-apheresis DFPP treatment and the associated cardiovascular and thromboembolic events will be described in these patients. Additionally, the impact of DFPP on biological and clinical markers including LDL cholesterol, triglycerides, fibrinogen, hemoglobin, platelet count, C-reactive protein (CRP), blood pressure, plasma volume treated, volume of albumin substitution, volume of plasma rejected, and duration of each Lipoprotein-apheresis DFPP session will be evaluated .
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| serum Lp(a) concentration (nmol/L), on routine venous blood sampling | Before and after each DFPP session (repeated measures) during the study period | up to 15 months after inclusion |
| Measure | Description | Time Frame |
|---|---|---|
| serum LDL and serum triglycerides concentration (g/L), on routine venous blood sampling | before and after each DFPP session (repeated measures) during the study period | up to 15 months after inclusion |
| serum triglycerides concentration (g/L), on routine venous blood sampling |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
chronic Hemodialsisi patients
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Zead TUBAIL, MD | CHR Metz-Thionville Hopital de Mercy | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHR Metz-Thionville Hopital de Mercy | Metz | 57085 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
before and after each DFPP session (repeated measures) during the study period |
| up to 15 months after inclusion |
| cardiovascular or thromboembolic events | Myocardial infarction, stroke, Deep vein thrombosis, Pulmonary embolism, Systemic arterial embolism, aortiques complictions, thrombosis, Based on patient questioning and clinical examination during routine follow-up consultations | during all the study period: up to 15 months after inclusion |
| Hemodynamic status:blood pressure | follow-up of patients' blood pressure (mmHg) before and after each DFPP session (repeated measures) during the study period | up to 15 months after inclusion |
| Hemodynamic status: ultrafiltration rate | follow-up of patients' ultrafiltration rate (grams) before and after each DFPP session (repeated measures) during the study period | up to 15 months after inclusion |
| ID | Term |
|---|---|
| D051436 | Renal Insufficiency, Chronic |
| ID | Term |
|---|---|
| D051437 | Renal Insufficiency |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided